- Home
- VERO vs INDP Comparison
VERO vs INDP Comparison
Compare VERO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- INDP
- Stock Information
- Founded
- VERO N/A
- INDP 2000
- Country
- VERO Canada
- INDP United States
- Employees
- VERO N/A
- INDP N/A
- Industry
- VERO Medical/Dental Instruments
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- INDP Health Care
- Exchange
- VERO Nasdaq
- INDP Nasdaq
- Market Cap
- VERO 4.3M
- INDP 4.0M
- IPO Year
- VERO N/A
- INDP N/A
- Fundamental
- Price
- VERO $2.14
- INDP $3.45
- Analyst Decision
- VERO
- INDP Strong Buy
- Analyst Count
- VERO 0
- INDP 1
- Target Price
- VERO N/A
- INDP $140.00
- AVG Volume (30 Days)
- VERO 206.6K
- INDP 532.3K
- Earning Date
- VERO 11-13-2025
- INDP 11-07-2025
- Dividend Yield
- VERO N/A
- INDP N/A
- EPS Growth
- VERO N/A
- INDP N/A
- EPS
- VERO N/A
- INDP N/A
- Revenue
- VERO $60,107,000.00
- INDP N/A
- Revenue This Year
- VERO N/A
- INDP N/A
- Revenue Next Year
- VERO $10.00
- INDP N/A
- P/E Ratio
- VERO N/A
- INDP N/A
- Revenue Growth
- VERO N/A
- INDP N/A
- 52 Week Low
- VERO $2.06
- INDP $2.22
- 52 Week High
- VERO $14.50
- INDP $47.60
- Technical
- Relative Strength Index (RSI)
- VERO 40.32
- INDP 44.84
- Support Level
- VERO $2.16
- INDP $3.41
- Resistance Level
- VERO $2.37
- INDP $3.76
- Average True Range (ATR)
- VERO 0.14
- INDP 0.44
- MACD
- VERO -0.02
- INDP 0.02
- Stochastic Oscillator
- VERO 13.70
- INDP 13.04
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.